Publications by authors named "C S Levetan"

This web-based survey of 311 respondents from 25 countries provides additional information about the early presentation of Rubinstein-Taybi syndrome. Most (86%) infants present during the neonatal period, with 69% of these within 24 hours of life. Prolonged hospital stay is common (61%).

View Article and Find Full Text PDF

On 31 October 1920, Sir Frederick Banting, while preparing for a medical student lecture on diabetes, a topic that he knew little about, learned how pancreatic stones resulted in the formation of new islets of Langerhans. He then scribbled down a potential research study of tying off the ducts of the pancreas and collecting the secretions to improve diabetes. These secretions became known as insulin.

View Article and Find Full Text PDF

Introduction: Gestational age is a strong determinant of neonatal mortality and morbidity. Early obstetric ultrasound is the clinical reference standard, but is not widely available in many developing countries.

Methods: A prospectively designed diagnostic accuracy study in a tertiary referral hospital in a developing country.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the diagnosis pathway for lymphoma in Sub-Saharan Africa, highlighting challenges such as confusion with extrapulmonary tuberculosis (EPTB), especially in HIV-positive patients.
  • Patients waited a median of 4 weeks before seeking medical help, followed by another 7 weeks for diagnosis, with longer delays linked to late-stage disease and Hodgkin lymphoma.
  • Despite delays in diagnosis, HIV status did not significantly impact timing, while patients receiving tuberculosis therapy experienced longer diagnostic times, indicating a need for better education on recognizing lymphoma symptoms.
View Article and Find Full Text PDF

Background: Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic phase chronic myeloid leukemia (CML-CP) experience intolerable adverse events. Management strategies include dose adjustments, interrupting or discontinuing therapy, or switching to an alternative TKI.

Methods: This multicenter, single-arm, Phase IIIb study included CML-CP patients intolerant of, but responsive to, first-line treatment with imatinib or dasatinib.

View Article and Find Full Text PDF